ArticleVox sanguinis2026
Potential benefits of an alternative haemoglobin deferral strategy evaluated in seven countries.
Article in Vox sanguinis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- What is the impact of whole-blood donation frequency on donor health? A systematic review.Vox sanguinis · 2026Pooled it
- Article
- Potential benefits of an alternative haemoglobin deferral strategy evaluated in seven countries.Vox sanguinis · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
17 authors.
Funding
Abstract
BACKGROUND AND
objectivesOn-site donor deferral for low haemoglobin (Hb) levels poses significant challenges for blood establishments globally, leading to material wastage and consumption of valuable staff and donor time. Traditionally, donors are deferred based on a single visit's Hb measurement, without considering previous Hb levels and measurement variability. This study aims to quantify, in different settings, the potential impact of an alternative deferral algorithm based on historical mean Hb levels. MATERIALS AND
methodsWe retrospectively reassessed donor eligibility in 20,430,816 donations and deferrals in Australia, Belgium, Finland, France, the Netherlands, South Africa and the United States using an algorithm that considers a repeat donor eligible as long as their historical mean Hb is above the deferral threshold and deviations from the mean are consistent with anticipated measurement variability. We quantified the potential impact of the alternative algorithm by calculating the change in donations and deferrals.
resultsAcross countries, the alternative algorithm may reduce low Hb deferrals between 30% and 70%. Additionally, in every country, a small proportion of current donors (~1%) donate who exhibit consistent low Hb levels. Balancing new deferrals and donations, the estimated net increase in donations across countries ranges between 0.7% and 3.3%.
conclusionThe alternative deferral algorithm based on mean Hb levels is a first step towards a more comprehensive assessment of Hb levels to determine donor eligibility. Further research is needed to refine the algorithm, to determine its long-term impact, to improve the model with information related to iron stores and recovery and to address the impact on donor safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.